Federal Policy

The DEA isn’t stepping back; it’s stepping in. While the industry celebrates the end of 280E, the fine print of the new Schedule III order reveals a mandatory federal middleman, undisclosed fees, and a legal “prescription” trap that could leave dispensaries in limbo. Here is what the rescheduling order actually means for your bottom line.

AI arrived wearing a suit, and cannabis arrived wearing tie-dye. It’s time we talk about why American capital is more responsive to costume than risk.

A potential move of cannabis to Schedule III could eventually reshape the industry’s tax burden by ending the reach of Section 280E. But operators should not confuse political momentum with immediate relief. A CPA explains why retroactive tax refunds are unlikely and disciplined compliance still matters. From defensible cost accounting to scenario planning and entity-structure review, the smartest path is cautious preparation rather than reactive change.

According to a new report from Americans for Safe Access, impending federal changes to hemp definitions could strip access from veterans, seniors, and those with rare diseases who rely on full-spectrum products.

Rescheduling may bring long-awaited 280E relief and a new sheen of mainstream legitimacy, but it also opens the door to federal-grade oversight, GMP expectations, stricter lender requirements, and expanded liability exposure. The “extra” cash operators anticipate could be quickly absorbed by compliance upgrades, professional services, and risk management. For CEOs, COOs, and CFOs, reclassification isn’t a finish line. It’s the starting gun for a tougher operational race.